Posters

  1. Impact Of The Genome Length Of Adeno-Associated Viral Vectors On Yield And Quality 1/13/2025

    In this study, we investigated the impact of transgene size on rAAV9 production using our platform and compared a wild-type-sized transgene cassette (4.7 kb) to a smaller, medium-sized cassette (3.0 kb).

  2. A Versatile Suspension-Based Platform For The Manufacturing Of AAVs 1/13/2025

    See how we leverage our flexible, modular platform to streamline AAV gene therapy manufacturing, reduce costs, and meet evolving regulatory standards.

  3. Impact Of Sample Treatment On DNA Length Distribution Analysis By Duplex 1/13/2025

    Ensure thorough characterization of rAAV plasmid impurities with our novel duplex ddPCR method to assess gene fragment length distribution and mitigate potential risks of horizontal gene transfer.

  4. Fit From Development To Manufacturing – A Successful rAAV9 Scalability Study In A Suspension Process Using HEK293 1/13/2025

    The goal of this study is to demonstrate the scalability of AAV productivity and the consistency of product quality across different bioreactor scales using Ascend’s AAV manufacturing platform.

  5. A Comprehensive ddPCR Portfolio For In-Depth DNA Impurity Profiling 1/13/2025

    Consider this duplex method for monitoring residual DNA impurities of different origins and review key aspects of method development and the qualification/validation of such assays.

  6. Combination Of BMI, DLS And Visual Inspection To Resolve Particle Formulation Issues In Formulations Commonly Used In Gene Therapy 1/13/2025

    Uncover how we utilized Backgrounded Membrane Imaging (BMI) alongside Dynamic Light Scattering (DLS) and Visual Inspection (VI) to identify optimal buffer conditions and mitigate particle formation.

  7. Transcriptomic Analysis Identifies Differential Expression Patterns In Cellular Stress Response, Signal Transduction, And Extracellular Matrix Proteins During AAV Production 1/7/2025

    We encourage further investigation into the identified pathways to optimize rAAV production processes, enhancing yields and vector quality for more scalable and effective gene therapies.

  8. Modular, Scalable AAV Purification Process For Safe Vectors And Recoveries Of Up To 50% 1/7/2025

    We encourage the adoption and further optimization of this scalable AAV downstream process platform to enhance gene therapy applications, ensuring high product yield, quality, and compliance.

  9. Successful Validation Of Capsid Titer And Host-Cell Derived DNA Impurity Assays Extends Our rAAV Batch Release QC Portfolio 1/7/2025

    This study introduces validated methods for quantifying AAV9 capsid titer and host-cell-derived impurities, offering a robust, adaptable solution for enhancing rAAV batch release testing under GMP conditions.

  10. Nanopore Sequencing Grants Detailed Insights Into A ​Small Molecule's Impact On Encapsidated DNA​ Composition During Manufacturing Platform Development 1/7/2025

    Utilize these findings and the power of nanopore sequencing to optimize rAAV vector production and advance gene therapy development.